Navigation Links
New details on the molecular machinery of cancer
Date:2/11/2013

Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley have provided important new details into the activation of the epidermal growth factor receptor (EGFR), a cell surface protein that has been strongly linked to a large number of cancers and is a major target of cancer therapies.

"The more we understand about EGFR and the complex molecular machinery involved in the growth and proliferation of cells, the closer we will be to developing new and more effective ways to cure and treat the many different forms of cancer," says chemist Jay Groves, one of the leaders of this research. "Through a tour-de-force of quantitative biology techniques that included cutting edge time-resolved fluorescence spectroscopy in living cells, Nuclear Magnetic Resonance, and computational modeling, we've determined definitively how EGFR becomes activated through to its epidermal growth factor (EGF) ligand."

Groves, who holds joint appointments with Berkeley Lab's Physical Biosciences Division and UC Berkeley's Chemistry Department, and is also a Howard Hughes Medical Institute (HHMI) investigator is one of two corresponding authors of a paper in the journal Cell that describes this research. The paper is titled "Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor." The other corresponding author is John Kuriyan, who also holds joint appointments with Berkeley Lab, UC Berkeley and HHMI.

In high school biology classes we learn that genes contain coded instructions that are translated into the assembly of specific proteins. Many proteins, however, must be activated by post-translational processes such as autophosphorylation, the addition of phosphate. Protein activation can impact many important cellular processes including proliferation, differentiation and migration. Cancer is essentially a case of these cellular functions gone wild, often the result of problems with the EGFR. However, despite its well-established links to cancer, EGFR activation has only been partially understood.

"As a member of the large class of cell surface receptors known as receptor tyrosine kinases, EGFR features a ligand-binding domain on its extracellular side and a kinase domain on its intracellular side," Groves says. "The text-book explanation for EGFR activation is that the binding of EGFR's ligand, EGF, to its extracellular side induces dimerization of the receptor, which in turn brings together the kinase domains on the intracellular sides of the dimer, allowing them to phosphorylate one another."

Groves says while the picture is accurate, it is an oversimplification of the mechanics behind the process because isolated intracellular kinase domains in solution can be active on their own at relatively low concentration without EGF ligand-induced dimerization. Dimerization is the combining of two identical molecules into a single compound molecule.

Measuring autophosphorylation as a function of EGFR surface density in cells, Groves, Kuriyan and their colleagues found that structural coupling between the EGFR transmembrane helix and extracellular juxtamembrane modules in addition to EGF ligand-engagement is required for EGFR activation. This structural coupling permits dimerization to take place in the presence of the EGF ligand.

"The un-ligated EGFR sits in a structural configuration that prevents the intracellular kinase domains from being able to reach each other," Groves says. "When the EGF ligand binds, this restraint is removed, dimerization occurs, and one kinase phosphorylates the other."

The inclusion by Groves and his colleagues of time-resolved fluorescence spectroscopy on living cells is another new advance in bringing a quantitative approach to the biological sciences. By combining picosecond light pulses from two different colors of lasers into a single beam, then genetically modifying EGFRs to carry either a red or green fluorescent protein, the researchers were able to monitor in real time how EGFRs move and assemble into dimers during activation by the EGF ligands.

"Focusing on the cell membrane and monitoring each fluorescent photon emitted, then determining both its color and precise time of arrival at the detector, allows unambiguous assignment of which photon was triggered by which color light pulse," Groves says. "All of this can be done in real time and in living cells."

With the mechanics behind the activation of EGFR now fully explained, Groves and his colleagues are now applying their quantitative biology techniques to another group of receptor tyrosine kinases, the Eph receptors, as well as T cell receptors that are so important to the immune system.

"Our broader goal with these quantitative biology techniques is to transform biology into a hard physical science," Groves says. "The idea is to move from simply describing a collage of observations to being able to understand how biological systems work based on fundamental physics."


'/>"/>

Contact: Lynn Yarris
lcyarris@lbl.gov
510-486-5375
DOE/Lawrence Berkeley National Laboratory
Source:Eurekalert  

Related medicine news :

1. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
2. Stanford/Intel study details power of new chip to diagnose disease, analyze protein interactions
3. Study details bullying involvement for adolescents with autism spectrum disorder
4. Report Details Start of Steroid Meningitis Outbreak
5. MyPuress Releases Details About Groundbreaking New Product
6. IOM report details strategy for monitoring safety of childhood immunization schedule
7. Institute of Medicine report details for monitoring safety of childhood immunization schedule
8. Scans Show Details of Damage to Soldiers With Head Injuries
9. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
10. Molecular probes identify changes in fibronectin that may lead to disease
11. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New details on the molecular machinery of cancer
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern Illinois ... are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy ... Gateway Convention Center in Collinsville. , They expect to treat approximately ...
(Date:6/24/2016)... Austin, TX (PRWEB) , ... June 24, 2016 , ... ... laude graduate, joins Evans Dermatology in the South Lamar location as of July 13, ... Texas Southwestern Medical School. As a medical student, she regularly volunteered at the Agape ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: